Wikipedia

Search results

Showing posts with label Mounjaro. Show all posts
Showing posts with label Mounjaro. Show all posts

Wednesday, 31 December 2025

Bloomin' Good News! Bloom Juice Co. Launches the UK’s First Dedicated GLP-1-Friendly Smoothie Range

Bloom Juice Co., the innovative café chain known for its unique and exciting offering of made-to-order Juice, Matcha and Acai ranges, today announces the launch of the UK’s first dedicated GLP-1-friendly smoothie range, marking a new step in how high-street cafés respond to changing customer needs around appetite, fullness and everyday nutrition.

The launch comes amid a rapid rise in awareness and use of GLP-1 medications such as Ozempic, Wegovy and Mounjaro across the UK. 

Recent consumer data shows usage of GLP-1 treatments has nearly doubled, increasing from around 2% of adults to approximately 4.4%, as more people explore new approaches to managing appetite and weight. Estimates suggest around 1.5 million adults in the UK are now using GLP-1 medications privately or via the NHS.

As these treatments become more widely discussed, eating habits are shifting. Many people report seeking out smaller, more satisfying options that feel filling without being heavy, overly sweet or high in calories, a change already being felt across the food and drink industry.

“At Bloom Juice Co., we’ve always paid close attention to how people actually eat and drink day to day,” Jordan Dodd, Regional Manager at Bloom Juice Co., told That's Food and Drink.

“GLP-1 medications are part of a much bigger conversation about appetite, balance and how food fits into modern life. 

"Our new range is about meeting customers where they are, whether they’re using GLP-1s or simply looking for something that keeps them feeling satisfied for longer.”

Designed for How People Eat Now

The new GLP-1-friendly smoothie range has been developed in-house to focus on texture, balance and satisfaction, rather than quick sweetness. Each of the 3 new smoothies is blended using carefully selected ingredients that support fullness and steady energy, in 3 unique flavours, covering breakfast, greens and treat-style flavourings.

Key features of the range include:

Higher protein and fibre content, to support appetite control

Lower sugar profiles, making them GLP-1 Friendly

Meal Supplements, designed to feel indulgent and filling

The range is designed to be enjoyed by anyone, whether they are using GLP-1 medications or simply prefer food and drink that feels more satisfying.

“We didn’t want to create ‘diet’ smoothies,” added Dodd. “We wanted drinks that feel premium, enjoyable and worth the visit; the kind of thing you’d choose because it tastes great, and then notice you feel good afterwards too.”

A First for the UK High Street

While GLP-1 medications are increasingly shaping conversations around food and appetite, Bloom Juice Co. believes it is the first UK café chain to introduce a clearly defined GLP-1-friendly range within a mainstream, high-street setting.

The new smoothies are available from 5th January 2026 across Bloom Juice Co. stores alongside their wider New Year Menu and will be supported by in-store and digital menu highlights to help customers navigate the range easily. The new range includes a new focus on supporting cognitive and digestive functions, as well as energy and wellness focussed.

Bloom Juice Co is a fast growing innovation-led cafe chain launched in 2024 with stores in Cambridge, Derby, Leeds & Lincoln, serving in-house made-to-order juice blends, smoothies, Acai bowls & ceremonial matcha.

https://www.bloomjuice.co.uk

Thursday, 1 May 2025

Pros and Cons of Weight Loss Injections

Weight loss injections like Wegovy (semaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) have gained popularity in the UK for aiding weight management and treating type 2 diabetes

These medications function by mimicking hormones that regulate appetite and digestion, leading to reduced calorie intake and weight loss.

How Do Weight Loss Injections Work?

These drugs are primarily GLP-1 receptor agonists, which imitate the glucagon-like peptide-1 hormone. This hormone stimulates insulin secretion, suppresses appetite by signaling satiety to the brain, and slows gastric emptying, prolonging the feeling of fullness. 

Tirzepatide, found in Mounjaro, also targets GIP receptors, enhancing its appetite-suppressing effects .

Are They Safe?

Clinical trials have demonstrated that these injections can lead to significant weight loss—up to 20% of body weight in some cases—and may reduce the risk of heart attacks, strokes, and complications from type 2 diabetes. But they aren't without risks.

Common side effects include nausea,vomiting, diarrhoea, constipation and heartburn.

Serious Risks include pancreatitis gallbladder disease, kidney problems, gastroparesis (delayed stomach emptying) and animal studies indicated that thyroid tumours could be a risk.

Some users have reported mental health concerns, including depression and anxiety, though evidence on this is still emerging.

Are There Long-Term Side Effects?

Long-term data is still being collected, but some users have reported persistent side effects even after discontinuing the medication. These include ongoing gastrointestinal issues, hair loss and dizziness. The potential for long-term complications such as thyroid tumours and gallbladder disease necessitates careful monitoring.

Final Thoughts

Weight loss injections offer a promising option for individuals struggling with obesity and related health issues. However, they are not a one-size-fits-all solution and come with potential risks. It's crucial to consult with a healthcare professional to determine if these medications are appropriate for your situation and to ensure proper monitoring during treatment.

For further information on the benefits and risks of weight loss injections, you can refer to the British Heart Foundation's overview here https://www.bhf.org.uk/informationsupport/heart-matters-magazine/news/behind-the-headlines/weight-loss-injections

Monday, 31 March 2025

Weight loss injections. Do they work? How much are they?

In recent years, weight loss injections have emerged as a significant tool in combating obesity in the UK. 

Medications like Wegovy, Saxenda, and Mounjaro have gained attention for their effectiveness in aiding weight reduction when combined with lifestyle changes. 

This article explores the companies offering these treatments, their efficacy, safety profiles, and associated costs.​

Companies Offering Weight Loss Injections in the UK

Several pharmaceutical companies and healthcare providers offer weight loss injections:​

Wegovy (Semaglutide): Manufactured by Novo Nordisk, Wegovy has been approved by the National Institute for Health and Care Excellence (NICE) for use within the NHS. It is also available through private healthcare providers.​

Saxenda (Liraglutide): Also produced by Novo Nordisk, Saxenda is accessible via the NHS for individuals meeting specific criteria and can be obtained privately.​

Mounjaro (Tirzepatide): Developed by Eli Lilly, Mounjaro is available through private clinics and online pharmacies in the UK.​

Effectiveness of Weight Loss Injections

Clinical studies have demonstrated the efficacy of these medications:​

Wegovy: In a 68-week trial, participants experienced an average weight loss of 15.8% of their initial body weight. ​

Saxenda: The same study reported a mean weight loss of 6.4% over 68 weeks. ​

Mounjaro: Clinical trials have shown weight reductions ranging from 15% to 20% of initial body weight. ​

Safety and Side Effects

While effective, these injections may cause side effects, typically mild but diminishing over time:​

Common Side Effects: Nausea, diarrhoea, constipation, headache, fatigue, dizziness, stomach pain, and upset stomach. ​

Serious Risks: Rare but severe side effects can include pancreatitis. Users are advised to consult healthcare professionals for personalised advice and monitoring. ​

Cost of Weight Loss Injections

The cost varies depending on the medication and provider:​

thedietologist.co.uk

Wegovy: NICE lists prices ranging from £124.54 to £175.80 per pack, depending on the dosage. ​

Saxenda: Approximately £196.20 for a pack of five 3ml pens. ​

Mounjaro: Prices start from £188.99 per pen. ​

These treatments may be available on the NHS for individuals meeting specific criteria; otherwise, they can be accessed through private healthcare channels.​

However, some local NHS Trusts routinely decline to prescribe weight loss injections on cost grounds, often blaming dubious 'clinical reasons.'

Conclusion

Weight loss injections like Wegovy, Saxenda, and Mounjaro offer promising avenues for individuals struggling with obesity. While they have shown significant effectiveness, it is crucial to consider potential side effects and consult healthcare providers to determine the most appropriate treatment plan. Costs can be substantial, but eligibility for NHS coverage may alleviate financial burdens for some patients.